ALEXANDRIA REAL ESTATE EQUITIES INC
For the period ended Mar 31, 2025. Filed Apr 28, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 28, 2025
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-09-30; filed 2024-10-21.
0001035443-24-000298
Item 1A. RISK FACTORSCurrent report: 10-Q
Period ended 2025-03-31; filed 2025-04-28.
0001035443-25-000136
Item 1A. RISK FACTORSThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 37 previous paragraphs and 103 current paragraphs.
6 unchanged; 3 reworded; 94 added; 28 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
There have been no material changes in our risk factors from those disclosed under the caption “Item 1A. Risk factors” in our
Added paragraphs (94)
Current report
Changes to regulatory, funding, staffing, trade, and other policies and actions by the current U.S. government
Current report
could adversely affect our business operations or those of our tenants and our venture investment portfolio
Current report
Domestic and international policy shifts may introduce considerable uncertainty to the macroeconomic and regulatory
Current report
landscape in which we, our tenants, and our venture investment portfolio companies operate. Our tenants and our venture
Current report
investment portfolio companies include entities in the pharmaceutical, biotechnology, medical device, life science and related
Current report
industries, academic institutions, government institutions, and private foundations that determine their research and
Current report
development budgets based on several factors, including the availability of government and other funding, and the operational
Current report
Since January 2025, the current U.S. administration has enacted and proposed substantial policy changes that affect
Current report
federal health agencies, research funding, public health priorities, and international trade. These measures — ranging from
Current report
staffing and budget reductions at the U.S. Food and Drug Administration (“FDA”) and the National Institutes of Health (“NIH”) to
Current report
sweeping tariff actions, as described below — may significantly disrupt the life science ecosystem in which we, our tenants, and
Current report
our venture investment portfolio companies operate.
Current report
On April 1, 2025, the FDA underwent layoffs of approximately 3,400 employees, representing greater than 15% of its
Current report
workforce. Such workforce reductions at the FDA have raised concerns regarding the agency’s capacity to perform timely
Current report
regulatory reviews and approvals of drugs and other medical products. Recent and/or potential further reductions in workforce
Current report
or other personnel changes at the FDA, including terminations, may disrupt the agency’s review and approval processes for our
Current report
tenants’ and our venture investment portfolio companies’ products. Such disruptions could lead to setbacks in research and
Current report
development timelines, negatively impacting life science companies’ ability to advance their pipelines, secure investor funding,
Current report
or achieve commercial viability, which could severely affect their operations and financial performance and, as a result,
Current report
adversely impact our operating and financial results.
Current report
NIH Grant Cuts and Impact on Research Institutions
Current report
The current U.S. administration has implemented significant policy changes affecting the NIH and leading to
Current report
substantial disruptions in biomedical research across the U.S. These actions included staff layoffs and funding cuts, as
Current report
described below, and resulted in the suspension of numerous research projects, posing risks to scientific advancement and
Current report
introducing significant uncertainty for some of our tenants and venture investment portfolio companies.
Current report
•NIH budget freeze. On January 27, 2025, the U.S. administration issued an executive order to suspend NIH grant
Current report
funding, freezing much of NIH’s approximately$47 billion budget for 2025. Though the suspension was eventually
Current report
blocked and reversed, the NIH subsequently laid off nearly 1,200 employees, with potential plans to eliminate up to
Current report
5,000 positions across its approximately 20,000-person workforce.
Current report
•Termination of NIH’s grants and funding commitments to major research institutions. On January 20, 2025, President
Current report
Trump issued an executive order directing every U.S. agency, including the NIH, to “terminate, to the maximum extent
Current report
allowed by law” all grants relating to diversity, equity, and inclusion. On January 29, 2025, the President issued an
Current report
executive order to make it “the policy of the United States to combat anti-Semitism vigorously, using all available and
Current report
appropriate legal tools, to prosecute, remove, or otherwise hold to account the perpetrators of unlawful anti-Semitic
Current report
harassment and violence.” As a result of one or both executive orders, the NIH, the world’s largest funder of
Current report
biomedical research, has withheld funding from certain U.S. research institutions.
Current report
•15% cap on indirect cost reimbursements of all NIH grants. On February 7 , 2025, the NIH introduced a policy limiting
Showing the first 40 of 94 passages. Open the source sections for the rest.
Removed paragraphs (28)
Previous report
The increased use of artificial intelligence (“AI”) and automation in life science research and development
Previous report
(“R&D”) activities may change the uses, space configurations and tenant requirements for our laboratory properties
Previous report
In recent years, some life science companies have augmented their traditional laboratory-based R&D efforts by
Previous report
integrating AI, cloud computing, quantum computing and other advanced computational technologies into their R&D programs.
Previous report
It is expected that such technologies will accelerate and streamline a number of R&D functions, including, for example, through
Previous report
the targeted design and evaluation of clinical trials and the efficient identification of the most promising drug development
Previous report
candidates from among multiple possible drugs. In addition, life science companies, like companies in many other industries,
Previous report
are increasingly integrating new technologies, such as robotics and advanced automation of recurring tasks, into their
Previous report
businesses, including their R&D activities. It is widely thought that the life science and healthcare industries, like most
Previous report
industries, are in only the early stages of an advanced technology revolution that may have profound, and largely currently
Previous report
unknown, impacts on their businesses, including the processes and strategies underlying R&D and commercialization of new
Previous report
We have always strived to provide our tenants with state-of-the-art laboratory facilities incorporating cutting-edge
Previous report
infrastructure features (including energy delivery, environmental, sustainability, security, and waste disposal features) to enable
Previous report
our tenants to perform at the highest levels. It is currently unknown how the ongoing adoption of advanced technologies and
Previous report
automation in the life science industry will impact the optimal space configurations and infrastructure features of the “laboratory
Previous report
of the future,” and we may face new tenant requirements and requests that will require significant expenditures that may not be
Previous report
entirely recoverable through increased rents. For example, the adoption of AI by our tenants may lead to infrastructure
Previous report
requirements that our buildings currently do not accommodate, such as increased power needs due to high-performance
Previous report
computing. Infrastructure upgrades may necessitate substantial capital expenditures and could potentially impact the
Previous report
environmental footprint of our building operations.
Previous report
If technological developments result in a reduction or reconfiguration in space requirements by our tenants, demand by
Previous report
individual tenants and prospective tenants for space may decrease over time. If we are not able to offset any reduction in demand from
Previous report
the foregoing developments through repurposing space, property dispositions, or other means, the realization of any of the
Previous report
aforementioned risks could have a material adverse impact on our revenues, net operating income, results of operations, funds from
Previous report
operations, operating margins, occupancy, earnings per share, FFO per share, our overall business, and the market value of our
Reworded paragraphs (3)
Previous wording
contained under the caption “Item 1A. Risk factors” in our annual report on Form 10-K for the year ended December 31, 2023. Those
Current wording
contained under the caption “Item 1A. Risk factors” in our annual report on Form 10-K for the year ended December 31, 2024. Those risk
Previous wording
risk factors could materially affect our business, financial condition, and results of operations. The risks that we describe in our public
Current wording
factors could materially affect our business, financial condition, and results of operations. The risks that we describe in our public filings
Previous wording
filings are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we presently deem to be
Current wording
are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we presently deem to be